Biomarkers for cancer-related fatigue and use thereof
AssigneesServices, The United States of America, as represented by the Secretary, Department of Health and Human
InventorLeorey N. Saligan
Life of this patent
Estimating the term…
Loading patent…
AssigneesServices, The United States of America, as represented by the Secretary, Department of Health and Human
InventorLeorey N. Saligan
Estimating the term…
Described herein is the identification of genes that are significantly up- or down-regulated in patients suffering from cancer-related fatigue (CRF), providing a means for the diagnosis and treatment of CRF. In particular, provided herein is a method of diagnosing a subject with CRF by detecting expression of at least one gene associated with CRF in a sample obtained from the subject; and comparing expression of the at least one gene to a control. Also described herein is a method of treating a patient with CRF by administering to the subject an agent that alters expression or activity of a gene associated with CRF. Further provided is array that includes a plurality of genes associated with CRF, such as TNFRSF25, SLC6A8, OGT, SNCA, APBA2, CASK, OR2W3, MYL4, IL7R, ARHGEF10 and ITGA6.
A method of diagnosing a subject with cancer-related fatigue (CRF), comprising:
A method of treating a patient with CRF, comprising administering to the subject an agent that decreases expression or activity of SNCA, SLC25A37 or BCL2L1, or any combination thereof.
Dependencies are inferred from the claim text.